Literature DB >> 24296859

Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting.

Fadi Maged Shokry Gurgis1, William Ziaziaris, Lenka Munoz.   

Abstract

Mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MAPKAPK-2 or MK2) is a downstream substrate of the p38 MAPK responsible for the signaling events influencing inflammation, cell division and differentiation, apoptosis, and cell motility in response to a wide range of extracellular stimuli. After the failure of p38 MAPK inhibitors in clinical trials, MK2 was unveiled as a potential target to regulate inflammatory cytokines' mRNA stability and translation. Recent work suggests that this mechanism may underlie the pathophysiology of brain disorders associated with inflammation. In addition, MK2 is a prominent kinase that phosphorylates heat shock protein 27 (Hsp27), an intensively investigated biomarker of cancer progression. This phosphorylation decreases the chaperone properties of Hsp27, making MK2 an endogenous inhibitor of Hsp27. MK2 is also one of the major players in the signal transduction pathways activated in response to DNA damage. Experimental evidence highlights the role of MK2 in G(2)/M and the mitotic spindle checkpoints, two mechanisms by which MK2 contributes to the maintenance of genomic stability. Thus, MK2 is considered a good molecular target to increase, in combination with chemotherapeutic agents, the sensitivity of treatment, especially in p53-mutated tumors. This review looks at the functions of MK2 in inflammation, Hsp27 regulation, and cell cycle checkpoint control with a focus on brain pathologies. Analysis of MK2 signaling in various disease models and a summary of the data on MK2 inhibitors suggest novel indications for MK2 inhibitors in addition to their mainstream use against peripheral inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24296859     DOI: 10.1124/mol.113.090365

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  26 in total

1.  Mesenchymal MAPKAPK2/HSP27 drives intestinal carcinogenesis.

Authors:  Ana Henriques; Vasiliki Koliaraki; George Kollias
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

2.  Modulating ADME Properties by Fluorination: MK2 Inhibitors with Improved Oral Exposure.

Authors:  Juraj Velcicky; Achim Schlapbach; Richard Heng; Laszlo Revesz; Daniel Pflieger; Ernst Blum; Stuart Hawtin; Christine Huppertz; Roland Feifel; Rene Hersperger
Journal:  ACS Med Chem Lett       Date:  2018-03-20       Impact factor: 4.345

Review 3.  Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases.

Authors:  Feng Qian; Jing Deng; Gang Wang; Richard D Ye; John W Christman
Journal:  Curr Protein Pept Sci       Date:  2016       Impact factor: 3.272

4.  In silico insights into prediction and analysis of potential novel pyrrolopyridine analogs against human MAPKAPK-2: a new SAR-based hierarchical clustering approach.

Authors:  Kranthi Kumar Konidala; Uma Devi Bommu; Suneetha Yeguvapalli; Neeraja Pabbaraju
Journal:  3 Biotech       Date:  2018-08-23       Impact factor: 2.406

5.  The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1β-driven IL-6 secretion in glioblastoma cells.

Authors:  F M S Gurgis; Y T Yeung; M X M Tang; B Heng; M Buckland; A J Ammit; J Haapasalo; H Haapasalo; G J Guillemin; T Grewal; L Munoz
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

6.  Bu Shen Tiao Chong recipe restores diminished ovary reserve through the BDNF pathway.

Authors:  Tian Xia; Yu Fu; Shuang Li; Ruihong Ma; Zhimei Zhao; Baojuan Wang; Chune Chao
Journal:  J Assist Reprod Genet       Date:  2016-04-19       Impact factor: 3.412

7.  Oncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells.

Authors:  Lenka Munoz; Yiu To Yeung; Thomas Grewal
Journal:  Cancer Biol Ther       Date:  2016-01-21       Impact factor: 4.742

Review 8.  Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials.

Authors:  Mario Fiore; Stefano Forli; Fabrizio Manetti
Journal:  J Med Chem       Date:  2015-11-09       Impact factor: 7.446

Review 9.  The Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway as a Discovery Target in Stroke.

Authors:  Jing Sun; Guangxian Nan
Journal:  J Mol Neurosci       Date:  2016-02-03       Impact factor: 3.444

Review 10.  Heat shock protein 27 phosphorylation state is associated with cancer progression.

Authors:  Maria Katsogiannou; Claudia Andrieu; Palma Rocchi
Journal:  Front Genet       Date:  2014-10-06       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.